RxDoctor Payments Data

Joanna Mitri, MD

Internal Medicine · Boston, MANPI 1356582845

Payments from drug & device makers

$179,598in general payments, 2019–2025

Across 75 payments — averaging $2394.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Research Institute, Inc.$128K
  • Novo Nordisk$44K
  • Eli Lilly$5K
  • Novo Nordisk AS$2K
  • Orpyx Medical Technologies Inc.$500
  • Insulet Corporation$155
  • plus $375 from 5 others

What the payments were for

  • Consulting fees$42,79083%
  • Speaking & faculty fees$5001%
  • Travel & lodging$5,65311%
  • Food & beverage$2,6845%
  • Education$380%
  • Gifts$1190%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Kowa Research Institute, Inc.37$127,814
Novo Nordisk25$44,273
Eli Lilly1$4,950
Novo Nordisk AS1$1,530
Orpyx Medical Technologies Inc.1$500
Insulet Corporation3$155
Johnson & Johnson1$136
Mannkind Corporation2$119
Sanofi1$50
Boehringer Ingelheim2$38
Abbott1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,598 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$5,312
Medicare patients
38
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide94$103,197
JardianceEmpagliflozin102$87,911
OzempicSemaglutide38$53,304
MounjaroTirzepatide18$31,475
Tresiba Flextouch U-100Insulin Degludec36$27,643
JanuviaSitagliptin Phosphate18$23,751
Humalog Kwikpen U-100Insulin Lispro12$4,862
HumalogInsulin Lispro15$3,689
Nano 2nd Gen Pen NeedlePen Needle, Diabetic26$2,811
LantusInsulin Glargine,hum.Rec.Anlog14$2,643
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,584
Novolog FlexpenInsulin Aspart13$1,766
Ultra-Fine Short Pen NeedlePen Needle, Diabetic16$1,571
Ezetimibe24$990
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic16$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$87,911102 claims
Novo NordiskOzempic$44,273$53,30438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →